Altimmune Bilan de santé

Santé financière contrôle des critères 6/6

Altimmune possède un total de capitaux propres de $152.5M et une dette totale de $0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont $173.3M et de $20.8M.

Informations clés

Ratio d'endettement

US$0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$164.91m
Fonds propres	US$152.53m
Total du passif	US$20.82m
Total des actifs	US$173.35m

Mises à jour récentes de la santé financière

Pas de mise à jour

Recent updates

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de 0A4C ( $171.2M ) dépassent ses passifs à court terme ( $15.2M ).

Passif à long terme: Les actifs à court terme de 0A4C ( $171.2M ) dépassent ses passifs à long terme ( $5.7M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: 0A4C est sans dette.

Réduire la dette: 0A4C n'a aucune dette par rapport à il y a 5 ans, lorsque son ratio d'endettement était 0.7%.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: 0A4C dispose d'une piste de trésorerie suffisante pour plus d'un an sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: 0A4C dispose d'une marge de trésorerie suffisante pour 1.4 ans si le flux de trésorerie disponible continue de diminuer à un taux historique de 30.3 % chaque année.

Altimmune Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

Recent updates

Altimmune, Inc. to Report Q3, 2024 Results on Nov 12, 2024

High number of new directors

High number of new directors

Altimmune, Inc. Completes Enrollment in Phase 2B Impact Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (Mash)

Altimmune, Inc., Annual General Meeting, Sep 26, 2024

New major risk - Revenue and earnings growth

First half 2024 earnings released: US$0.69 loss per share (vs US$0.72 loss in 1H 2023)

New major risk - Revenue and earnings growth

Altimmune, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Altimmune, Inc. Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology

Altimmune, Inc. Announces Demise of Richard Eisenstadt, Chief Financial Officer

Altimmune, Inc. Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity at the American Diabetes Association’s 84th Scientific Sessions

Altimmune, Inc. Presents Data at EASL International Liver Congress™? 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$0.34 loss per share (vs US$0.40 loss in 1Q 2023)

Pomerantz LLP Announces Filing of Class Action Against Altimmune, Inc. and Certain Officers

Altimmune, Inc. to Report Q1, 2024 Results on May 09, 2024

Full year 2023 earnings released: US$1.66 loss per share (vs US$1.81 loss in FY 2022)

New major risk - Revenue and earnings growth

Altimmune, Inc. Announces Impairment Loss for the Three Months Ended December 31, 2023

Altimmune, Inc. to Report Q4, 2023 Results on Mar 27, 2024

New major risk - Share price stability

Altimmune, Inc. Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide

Third quarter 2023 earnings released: US$0.39 loss per share (vs US$0.48 loss in 3Q 2022)

Altimmune, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Altimmune, Inc. Grants Fast Track Designation by FDA for Pemvidutide for the Treatment of Non Alcoholic Steatohepatitis (Nash)

Altimmune, Inc., Annual General Meeting, Sep 28, 2023

Altimmune, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Altimmune, Inc. Announces Initiation of Phase 2b Impact Trial Evaluating the Efficacy and Safety of Pemvidutide in Non-Al Alcoholic Steatohepatitis

Altimmune, Inc. to Report Q1, 2023 Results on May 11, 2023

Altimmune, Inc. Appoints Raymond Jordt as Chief Business Officer

Altimmune, Inc. Announces Positive Topline Results from 24-Week (12-Week Extension) Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease

Third quarter 2022 earnings released: US$0.48 loss per share (vs US$0.81 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.48 loss per share (vs US$0.81 loss in 3Q 2021)

Altimmune, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Altimmune, Inc. Announces First Dosing of All Subjects in Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight

Altimmune, Inc. Announces Significant Reductions in Liver Fat Content and Body Weight in 12-Week Phase 1b Clinical Trial of Pemvidutide in Subjects with NAFLD

Altimmune, Inc., Annual General Meeting, Sep 29, 2022

Second quarter 2022 earnings released: US$0.42 loss per share (vs US$0.60 loss in 2Q 2021)

Altimmune, Inc. to Report Q2, 2022 Results on Aug 11, 2022

First quarter 2022 earnings released: US$0.44 loss per share (vs US$0.38 loss in 1Q 2021)

Altimmune, Inc. to Report Q1, 2022 Results on May 12, 2022

Insufficient new directors

Insufficient new directors

Altimmune Announces Initiation of 48-Week Phase 2 Momentum Trial of Pemvidutide in Obesity

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Altimmune Announces FDA Clearance of Pemvidutide (ALT-801) IND for Obesity

Insufficient new directors

Insufficient new directors

Third quarter 2021 earnings released: US$0.81 loss per share (vs US$0.54 loss in 3Q 2020)

Altimmune Announces Positive Results from 12-Week Phase 1 Clinical Trial of ALT-801 (Pemvidutide) in Overweight and Obese Volunteers

Altimmune, Inc. Reports an Impairment on Construction-In-Progress for the Three Months Ended June 30, 2021

Second quarter 2021 earnings released: US$0.60 loss per share (vs US$0.94 loss in 2Q 2020)

Altimmune Announces Update on AdCOVID™ Phase 1 Clinical Trial

Altimmune Announces Positive Interim Data from ALT-801 Phase 1 Trial in Overweight and Obese Volunteers

Forecast breakeven pushed back to 2024

Altimmune, Inc. Demonstrates Strong Neutralization of South African Variant in Preclinical Study of Intranasal AdCOVID™

First quarter 2021 earnings released: US$0.38 loss per share (vs US$0.26 loss in 1Q 2020)

Forecast breakeven pushed back to 2025

Altimmune Announces New Preclinical Data for AdCOVID™ Demonstrating Sterilizing Immunity After a Single Intranasal Dose

Altimmune, Inc. Announces Additional Preclinical Data for Its Single Dose Intranasal COVID-19 Vaccine Candidate, AdCOVID

Full year 2020 earnings released: US$1.91 loss per share (vs US$1.60 loss in FY 2019)

Revenue beats expectations

Altimmune, Inc. Commences Enrollment in Phase 1 Clinical Trial of AdCOVID- A Needle-Free, Single-Dose Intranasal Covid-19 Vaccine Candidate

Altimmune, Inc. to Report Fiscal Year 2020 Results on Feb 25, 2021

Altimmune, Inc. Announces FDA Clearance of AdCOVID™ IND Application

Altimmune, Inc. Begins Multinational Phase 2 Clinical Trial of HepTcellTM, a Novel Immunotherapeutic for the Treatment of Chronic Hepatitis B

Altimmune Provides an Update on its Investigational New Drug Application for a Phase 1 AdCOVID™ Clinical Trial

Altimmune Announces Submission of Investigational New Drug Application To the U.S. Food and Drug Administration to Commence A Phase 1 Clinical Study of Its Single-Dose Intranasal COVID-19 Vaccine Candidate, AdCOVID

Altimmune, Inc. Adds Lonza as a Manufacturing Partner for Supply of AdCOVID its Single-Dose Intranasal Vaccine Candidate for COVID-19

Altimmune, Inc. to Report Q3, 2020 Results on Nov 10, 2020

Altimmune and UAB Announces Publication of Compelling Pre-clinical Data for AdCOVID™ Intranasal COVID-19 Vaccine Candidate

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan